Latest Basiliximab Stories
SILVER SPRING, Md., June 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant.
In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug â€“ at one-half to one-fifth the price â€“ is as safe and effective as the other two.
Kidney transplant recipients who develop antibodies in response to receiving new organs can develop accelerated arteriosclerosis, or narrowing of the arteries that supply blood to the kidney.
Test monitors level of a drug that helps prevent kidney rejection SILVER SPRING, Md., Feb. 11, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients.
SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye.
- Emitting flashes of light; glittering.